Klin Farmakol Farm. 2013;27(2):80-83

Strategies of risk assessment of biological agents with aspect to rheumatoid arthritis

Milan Kriška1, Jozef Rovenský2
1 Ústav farmakológie a klinickej farmakológie LFUK Bratislava

The aim of the review is to inform about harmful effects of biological agents during the treatment of RA. The increasing number of new biological

agents presents a challenge in terms of their rational selection given their high cost as well as relative risk during long-term treatment.

Keywords: therapy of RA with biological agents, pharmacovigilance, risk of biological agents, registries

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kriška M, Rovenský J. Strategies of risk assessment of biological agents with aspect to rheumatoid arthritis. Klin Farmakol Farm. 2013;27(2):80-83.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.Fierce Biotech 2012.com
    2. Mayboom R. Pharmacovigilance in changing world. Editorial in Klinická farmakologie a farmacie 2011; 25: 102-111.
    3. www ŠUKL.sk www SUKL2012.
    4. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In Textbook of adverse reactions, ed Dawies, Oxford University Press 1977: 10.
    5. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaborationś tool for assessing risk of bias in randomised trials. Brit Med J 2011; 343d5928 doi. Go to original source... Go to PubMed...
    6. Askling J. Scientic Convention lecture, ENCePP session, EMA London 25 November 2008.
    7. Gallowy JB, Simmons DP, Lunt M, et al. Anti TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in first 6 months of treatment: uptodated results from the british Society Rheumatology Biologics Register with special emphasiss on risk in the elderly. Rheumatology 2011; 50: 124-131. Go to original source... Go to PubMed...
    8. Curtis JR, Xie F, Chen l, et al. The comparative risk of serious infections among rheumatoid arthritis patients Ann Rhematol Dis 2011; 70: 2331-2339. Go to original source... Go to PubMed...
    9. Horton SC, Nam JL, Buch MH. Safety of biologics in Rhematoid Arthritis CME Int J Clin Rheumatol 2012: in www. medscape.org. Go to original source...
    10. Dixon WG, Watson K, Lunt M, et al. Rates of serious infections, including site-specificand bacterial intracelular infections in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy resuts from the British Society for Rheumatology Biologics Register Arthritis Rheum 2006; 54: 2368-2376. Go to original source... Go to PubMed...
    11. Grijalva CG, Chen L, Delyall, et al. Anti TNF therapy is associated with an increased risk of serious infections in patients with rhematoid arthritis especialy in the first 6 month of treatment uptodated results from the British Socienty for Rheumatology Biologics Register with special emphasis on the risk in the elderly. Rheumatology 2011; 124: 123-131. Go to original source...
    12. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a antibody to tumor necrosis factor a given by monthly subcutaneous injectios, in active rheumatoid arthritis despite methotrexate therapy, the GO-FORWARD study. Ann Rheum Dis 2009; 8: 789-796. Go to original source... Go to PubMed...
    13. Fleishman R, Vencovsky J, Van Vollenhoven, et al. Efficacy a safety of certolizumab pegol monotherapy every 4 weeks in patints with reumatoid arthritis failing previous disease-modifying antirheumatic therapy. The FAST4WARD study, Ann Rheu.Dis 2009; 68: 805-811. Go to original source... Go to PubMed...
    14. Cohen SB, Emery P, Greewald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumoro necrosis factor therapy, results of a multicenter, randomised, double-blind, placebo controlled, Phase III trial evaluating primary efficacy and safety at twenty four weeks - Arthritis Rheumat 206; 54: 2793-2806. Go to original source...
    15. Saliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abacept and anakira treatment for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32. Go to original source... Go to PubMed...
    16. Singh JH, Wells Christensen R, et al. Adverse effects of biologics: a network meta-anlysis and Cohrane overview Cohrane Database Syst Rev. 2011; 2, CD008794.
    17. Schiff MA, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 23: R141. Go to original source... Go to PubMed...
    18. Pirpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis Rheumatol Int 201; 31: 403 Go to PubMed...
    19. Backwill F. TNF-alfa in promotion and progression of cancer Cancer Metastasis Rev 2006; 25: 409-416. Go to original source... Go to PubMed...
    20. www.FDA.com.
    21. ACR uptodates RA advice on DMARDs, Biologics, switching drugs Arthritis Care Res 2012; 64: 625-639. Go to PubMed...
    22. Gotze CP, Jorgensen AW. Opening data at the European Mediceines Agency BMJ 2011; 342: 26486-2690. Go to original source...
    23. EU Smernica. Commission implementing regulation (EU) No 520/2012 Official J of the EU 2012; I155/5.
    24. Kriška M, et al. Hodnotenie rizika liekov. Klin Farmakol a Farmac, 2011; 25: 122-125.
    25. Strom BL. editor Pharmaepidemiology Chicester John Wiley and Sons, 2000: s 874.
    26. www.CIOMS.com.
    27. Cíferská H, Horák P, Strojil J, et al. Biologická terapie v revmatologii. Klin Farmakol a Farmac 2010; 2: 197-206.
    28. Aronson JK. Risk perception in drug therapy. Br J Clin Pharmacol 2006; 62: 135-137. Go to original source... Go to PubMed...
    29. www ENCePP.com.
    30. Cundiff DK. Evidence-based medicine and the Cohrane collaboration.
    31. www.medscope.com 2009.
    32. Communication patient safety during pharmacotherapy, Smolenice 200 May 21-22, Kriska M, a spol. reports in Rheumatológia 20010; 24: 69-104.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.